Elevation Oncology股票討論

$Elevation Oncology(ELEV.US)$  Data expected readout of EO-3021 data in the latter half of 2024, which could showcase the efficacy and safety of the anti-Claudin 18.2 antibody-drug conjugate in treating advanced cancers.
Furthermore, preclinical data has shown that Elevation Oncology’s HER3-ADC candidate demonstrates significant antitumor activity, suggesting a strong foundation for future clinical evaluations

Hello Mooers!
A quick recap for the month ending April 30, 2024.
Ten stocks with >300% YTD
$Swvl Holdings(SWVL.US)$718.40%
$Root Inc(ROOT.US)$564.60%
$Elevation Oncology(ELEV.US)$561.08%
$JanOne(JAN.US)$554.05%
$GeneDx Holdings(WGS.US)$520.71%
$Corbus Pharmaceuticals(CRBP.US)$513.25%
$AGBA Group(AGBA.US)$482.90%
$Janux Therapeutics(JANX.US)$431.22%
$Dave Inc(DAVE.US)$4...

$Elevation Oncology(ELEV.US)$
NEWS
Elevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at AACR Annual Meeting 2024
Elevation Oncology announces promising preclinical data for its HER3-ADC program, showcasing proof-of-concept results at AACR Annual Meeting 2024. The data demonstrates HER3-dependent cell killing and robust anti-tumor activity in solid tumors with high HER3 expression. The company aims to nominate a development candidate later in 2024.

$Elevation Oncology(ELEV.US)$ If you bought when I said back in March 7 you d9bked your money here today !

$Elevation Oncology(ELEV.US)$ $Merrimack Pharmaceuticals(MACK.US)$   Merrimack Gets $225 Million Milestone Payment, Schedules Meeting For Dissolution Plan
MT Newswires· 2 mins ago
Merrimack Pharmaceuticals (MACK) said late Wednesday it has received a $225 million milestone payment from Ipsen and called for a special stockholder meeting on May 10 to approve a plan of dissolution.
The milestone payment was due from Ipsen after the US Food and Drug Administration approved Onivyde as a first-line...

$Elevation Oncology(ELEV.US)$ Taking a position here soon !

$Elevation Oncology(ELEV.US)$ Elevation Oncology Announced That It Has Expanded Its Ongoing Phase 1 Clinical Trial Of EO-3021 Outside The United States, Dosing The First Patient In Japan